1242093-99-7

Upstream product

• 69610-41-9 Boc-L-Pro-H 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 129012-04-0 2,3-Diamino-6-bromopyridine 
• 1242093-98-6 C₃₅H₄₁N₇O₄ 
• 1228553-64-7 C₁₅H₁₉BrN₄O₂ 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 1242093-98-6 C₃₅H₄₁N₇O₄ 
• 1228553-64-7 C₁₅H₁₉BrN₄O₂ 
• 1228968-40-8 C₂₃H₃₁N₃O₂Si 
• 1228968-41-9 2-[5-(4-ethynyl-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1242094-56-9 C₂₅H₂₅N₇ 

Relevant academic research and scientific papers

INHIBITORS OF HCV NS5A

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.